My bookmarksSign up free

Directive 2001/20/EC of the European Parliament and of the… Article 14

Directive 2001/20/EC of the European Parliament and of the… Article 14

Labelling

Article 14

The particulars to appear in at least the official language(s) of the Member State on the outer packaging of investigational medicinal products or, where there is no outer packaging, on the immediate packaging, shall be published by the Commission in the good manufacturing practice guidelines on investigational medicinal products adopted in accordance with Article 19a of Directive 75/319/EEC. In addition, these guidelines shall lay down adapted provisions relating to labelling for investigational medicinal products intended for clinical trials with the following characteristics: — the planning of the trial does not require particular manufacturing or packaging processes; — the trial is conducted with medicinal products with, in the Member States concerned by the study, a marketing authorisation within the meaning of Directive 65/65/EEC, manufactured or imported in accordance with the provisions of Directive 75/319/EEC; — the patients participating in the trial have the same characteristics as those covered by the indication specified in the abovementioned authorisation.

Read the full instrument →

Other provisions in Directive 2001/20/EC of the European Parliament and of the…

Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗ · Data as of 2026-07-04

CitationArticle 14 of Directive 2001/20/EC of the European Parliament and of the… (LawPlayer, data as of 2026-07-04)

© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.

What to look at next